checkAd

Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience - Seite 2

Nachrichtenquelle: Business Wire (engl.)
20.04.2021, 14:00  |  114   |   |   

Efficacy of Ruxolitinib Cream Among Patients with Atopic Dermatitis Based on Previous Medication History: Pooled Results from Two Phase 3 Studies (Abstract #27482)

Efficacy of Ruxolitinib Cream in Patients with Atopic Dermatitis Who Demonstrated Partial Responses: Pooled Analysis from Two Randomized Phase 3 Studies (Abstract #24916)

Ruxolitinib Cream Rapidly Decreases Pruritus in Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #26884)

Effects of Ruxolitinib Cream on Work Productivity and Activity Impairment in Patients with Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #28200)

Effect of Ruxolitinib Cream on Sleep Disturbance and Sleep Impairment: Pooled Analysis from Two Randomized Phase 3 Studies (Abstract #26887)

Patient-Reported Outcomes of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #28194)

Vitiligo (Category: Pigmentary Disorders & Vitiligo)

Addition of Narrow-Band Ultraviolet Light B Phototherapy to Ruxolitinib Cream in Patients with Vitiligo (Abstract #27636)

Correlation of the Vitiligo Area Scoring Index with Patient – and Physician-Reported Measures of Clinical Improvement in a Randomized, Double-Blind Phase 2 Study (Abstract #25486)

All presentations will be available on demand starting April 23, 2021, at 8 a.m. CT (9 a.m. ET), and can be accessed until July 12, 2021. Full session details and listings all presentations are available on the AAD VMX program: https://eposters.aad.org/categories.

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Seite 2 von 3
Incyte Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience - Seite 2 Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology Virtual Meeting Experience (AAD VMX), held virtually from April 23-25, …

Nachrichten des Autors

Titel
Titel
Titel
Titel